Evidence map›Paper›PMID 41265795›Full record

ArticleSLAS technology2025

Automated endpoint titer ELISAs for high-throughput immunogenicity evaluations using a BioMek i7 liquid handler.

Barbara Theriot, Andrew N Macintyre

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Barbara TheriotDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Andrew N MacintyreDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: a.n.macintyre@duke.edu.

Funding

Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1M
Regional Biocontainment Laboratory (RBL)UC6AI058607 · NIAID · DUKE UNIVERSITY · PI WILLIAMS, R SANDERS · 2003 to 2005
$16.3M
Resources and Workforce Development for the Regional Biocontainment LaboratoriesUC7AI180254 · NIAID · DUKE UNIVERSITY · PI Herman F Staats · 2023 to 2026
$14.0M
The Gonorrhea Vaccine Cooperative Research CenterU19AI144180 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI CHACKERIAN, BRYCE C · 2019 to 2023
$10.7M
The Atlantic Coast Sexually Transmitted Infection Cooperative Research Center (ACU19AI113170 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI JERSE, ANN E. · 2014 to 2018
$6.9M
Regional Biocontainment Laboratories Facility and Building System Upgrades SupportG20AI167200 · NIAID · DUKE UNIVERSITY · PI STAATS, HERMAN F · 2021 to 2022
$6.6M
NIAID NIH HHS 75N93019C00050NIAID NIH HHS G20 AI167200NIAID NIH HHS U19 AI113170NIAID NIH HHS U19 AI144180NIAID NIH HHS UC6 AI058607NIAID NIH HHS UC7 AI180254
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41265795
PMCPMC12683714

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.